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Abstract
Introduction
• Incidence of Autism Spectrum Disorder (ASD) in 8-year old 
children is 1 in 59. 
• Autism includes deficits in social emotional reciprocity, non-
verbal communication for social interactions, developing and 
maintaining relationships and in some cases, hyperactivity 
response to sensory input
• ASD often shares similar behavior profiles to ADHD. These 
behaviors include impulsiveness and hyperactivity. 
Research Questions
Literature Review
Applicability to Clinical 
Practice
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Causes for discontinuation of pharmacotherapy with 
methylphenidate in ADHD
• Of the 314 children in the study, two discontinued the treatment 
due to adverse events (Greenhill, Findling & Swanson, 2002).
• Of the 220 subject, there was one serious adverse event requiring 
discontinuation in which a subject threatened suicide (Wilens, et 
al., 2016).
Causes for discontinuation of pharmacotherapy with α 2-a 
receptor agonists in ASD
• None of the subjects discontinued use of clonidine during the trial 
due to adverse side effects (Jaselskis, Cook, Fletcher & 
Leventhal, 1992).
• In no case did side effects lead to discontinuation of guanfacine in 
this study (Posey, Puntney, Sasher, Kem & Mcdougle, 2004).
• 16% of subjects withdrew due to adverse effects associated with 
guanfacine (Scahill et al., 2006).
Causes for discontinuation of pharmacotherapy with α 2-a 
receptor agonists in ADHD
• The total rate of discontinuation due to side effects in this trial 
were GXR of 7.4% and placebo at 7.6% (Sallee et al., 2009).
• There were nine participants that ultimately withdrew from the 
study due to adverse effects (Wilens et al., 2015).
Hyperactivity is a shared behavior with ASD and Attention Deficit 
Hyperactivity Disorder (ADHD). Medications such as 
Methylphenidate (MPH) and α 2-a adrenergic receptor agonists are 
used to modify hyperactivity behavior in ADHD and thus have been 
used as management in ASD. A review of literature was done to 
evaluate the use of medications typically used for ADHD in the use 
of ASD. The databases searched included PubMED, PsycINFO, 
Cochrane, and Clinical Key. After reviewing the literature, it was 
found that both MPH and 2-a adrenergic receptor agonist have a 
potential role in pharmacotherapy for ASD. MPH may be slightly 
more effective at reducing hyperactivity-impulsivity behaviors than 
2-a adrenergic receptor agonist, however the side effect profile in 
MPH has led to more discontinuations over 2-a adrenergic receptor 
agonist. More studies would need to be conducted to validate the 
findings of this review. 
Keywords: ASD, ADHD, PDD-NOS, Asperger syndrome, autistic 
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1. In children with ASD, are psychostimulants, such as MPH as 
effective at reducing impulsivity-hyperactivity behaviors as 
compared to children with ADHD according to teacher and 
parent reports?
2. In children with ASD, are α 2-a adrenergic receptor agonists, 
such as clonidine and guanfacine, more effective at reducing 
impulsivity-hyperactivity behaviors as compared to 
psychostimulants such as MPH, according to teacher and parent 
reports?
3. Are the rates of discontinuation of pharmacotherapy in children 
with ASD higher in treatment with MPH vs clonidine or 
guanfacine?
Methylphenidate as a treatment for impulsivity-hyperactivity in 
ASD
• 8 out of 13 children were deemed responders to MPH (Handen, 
Johnson & Lubetsky, 2000).
• According to research conducted by RUPP, “Our response rate of 
49% is less than the previously described response rates of 70% 
to 80% seen in typically developing children with ADHD” 
• MPH was found to be superior to placebo at reducing 
hyperactivity (Quintana et al., 1995).
Methylphenidate as a treatment for impulsivity-hyperactivity in 
ADHD
• 80% of the 314 subjects were deemed responders to MPH 
(Greenhill, Findling & Swanson, 2002). 
• It was found that MPH was statistically significant over placebo. 
52% of 177 subjects in the active medication group achieved 
some benefit from MPH (Wilens et al., 2006). 
α 2-a receptor agonists as treatment for impulsivity-
hyperactivity in ASD
• 19 of the 80 subjects (23.8%) were deemed as “responder” 
(Posey, Puntney, Sasher, Kem & Mcdougle, 2004).
• Behaviors associated with Autism such as hyperactivity and 
impulsivity are often detrimental in various situations of life.
• The increasing incidence of autism is evidence that continued 
investigation and evaluation of the most efficacious medical 
management is needed to meet the needs of this increasing 
population. 
• By identifying the most efficient pharmacological therapy for 
these behaviors, providers can help to prescribe an appropriate 
medication regimen to improve quality of life for both patients and 
caregivers. 
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Statement of the Problem
• ASD and ADHD behaviors interfere negatively with daily living 
for children, peers, teachers and parents/caregivers, which makes 
day to day life difficult for both the child and others involved.
• Pharmacotherapy is often used to help manage these behaviors 
and to make daily living more manageable for the child and those 
around them. 
• The first line pharmacotherapy for children with ADHD is 
typically a stimulant. Due to similarities in behavior profiles, 
psychostimulants are used off-label for impulsivity-hyperactivity 
behaviors in children with ASD without a comorbid diagnosis of 
ADHD. 
• Research needs to be done to investigate the effectiveness of 
these medications in children with ASD to help explore further 
management of these behaviors.  
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Literature Review, cont.
• A study conducted by RUPP showed that 50% of participants 
were deemed responders to the active medication of guanfacine
Efficacy of α 2-a receptor agonists in ADHD
• Significant improvement was found in Clonidine over placebo 
(Jain et al., 2011). 
• Guanfacine was found to be superior to placebo (Newcorn et al., 
2013)
• All subjects receiving active guanfacine showed statistically 
significant improvement (Sallee et al., 2009).
Causes for discontinuation of pharmacotherapy with 
methylphenidate in the treatment of ASD
• There were no statistically significant side effects found when 
comparing MPH to placebo (Quintana, et al., 1995).
• Three of the thirteen children that participated in this study 
discontinued early due to adverse side effect (Handen, Johnson & 
Lubetsky, 2000).
• The number of subjects in the ASD studies ranged from 9-13 
compared to the ADHD studies which ranged from 220-314.
• The response rate to MPH in the ASD group ranged from 49-
61%, whereas, responders in the ADHD population ranged from 
52-81%. 
• MPH and α 2-a adrenergic receptor agonists were both found to 
be statistically significant at modifying impulsivity-hyperactivity 
behavior in children with Autism. 
• The most common reasons for discontinuation of MPH were 
irritability, crying, tantrums, skin picking and aggression
• The most common reasons for discontinuations of 2-a adrenergic 
receptor agonists were excessive fatigue, somnolence, irritability 
and emotional lability. 
• Further research needs to be conducted with large scale studies to 
validate the data found. 
